Long-Term Outcome and Risk Factors for Uncontrolled Seizures After a First Seizure in Children With Hematological Malignancies

Abstract

Long-term outcomes of seizures that develop during treatment of childhood hematological malignancies have not been described. We analyzed seizure outcome in 62 children with leukemia or lymphoma treated at our institution. There was a median follow-up of 6.5 years since first seizure. Seizure etiology included intrathecal or systemic methotrexate in 24, leucoencephalopathy in 11, brain hemorrhage or thrombosis in 11, meningitis in 4, and no identifiable cause in 12. Seizures remained uncontrolled in 18, and risk factors for poor control included female sex (P = .02), no seizure control with first antiseizure drug (P = .08), and longer interval between cancer diagnosis and seizure onset (P = .09). Poor seizure control after initial antiseizure drug also predicted recurrent seizure after drug withdrawal (P = .04). In conclusion, seizures are controlled with medications in a majority of patients with hematological cancer. After a period without seizures, antiseizure drug withdrawal in appropriately selected patient has a high success rate.

Keywords

leukemia lymphoma seizures outcome hematological malignancy methotrexate

Get full access to this article

View all access options for this article.

References

Howlader

Noone

Krapcho

. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2010. Available at http://seer.cancer.gov/csr/1975_2008/.

Iuvone

Mariotti

Colosimo

. Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia. Cancer. 2002;95:2562–2570.

Reddick

Shan

Glass

. Smaller white-matter volumes are associated with larger deficits in attention and learning among long-term survivors of acute lymphoblastic leukemia. Cancer. 2006;106(4):941–949.

Raymond-Speden

Tripp

Lawrence

Holdaway

. Intellectual, neuropsychological, and academic functioning in long-term survivors of leukemia. J Pediatr Psychol. 2000;25:59–68.

Ochs

Bowman

Pui

. Seizures in childhood lymphoblastic leukaemia patients. Lancet. 1984;2:1422–1424.

Mahoney

Jr Shuster

Nitschke

. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol. 2000;18:1285–1294.

Pui

Campana

Pei

. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360:2730–2741.

Maytal

Grossman

Yusuf

. Prognosis and treatment of seizures in children with acute lymphoblastic leukemia. Epilepsia. 1995;36:831–836.

Goldsby

Liu

Nathan

. Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2010;28:324–331.

10.

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on classification and terminology of the International League Against Epilepsy. Epilepsia. 1989;304:389–399.

11.

Bird

Hedberg

Drayer

. MR assessment of myelination in infants and children: usefulness of marker sites. Am J Neuroradiol. 1989;10:731–740.

12.

Kingma

Mooyaart

Kamps

. Magnetic resonance imaging of the brain and neuropsychological evaluation in children treated for acute lymphoblastic leukemia at a young age. Am J Pediatr Hematol Oncol. 1993;15:231–238.

13.

von der Weid

Mosimann

Hirt

. Intellectual outcome in children and adolescents with acute lymphoblastic leukaemia treated with chemotherapy alone: age- and sex-related differences. Eur J Cancer. 2003;39:359–365.

14.

Waber

Tarbell

Kahn

. The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol. 1992;10:810–817.

15.

Tripathi

Padhy

Vibha

. Predictors of refractory epilepsy in north India: a case-control study. Seizure. 2011;20(10):779–783.

16.

Relling

Pui

Sandlund

. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet. 2000;356:285–290.

17.

Gilbert

Supko

Batchelor

. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res. 2003;9:2940–2949.

18.

Kargiotis

Markoula

Kyritsis

. Epilepsy in the cancer patient. Cancer Chemother Pharmacol. 2011;67:489–501.

19.

French

Kanner

Bautista

. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1252–1260.

20.

Khan

Hunt

Boop

. Seizures in children with primary brain tumors: incidence and long-term outcome. Epilepsy Res. 2005;64:85–91.

21.

Specchio

Beghi

. Should antiepileptic drugs be withdrawn in seizure-free patients? CNS Drugs. 2004;18:201–212.

22.

Hauser

Freilinger

Seidl

Groh

. Prognosis of childhood epilepsy in newly referred patients. J Child Neurol. 1996;11:201–204.

23.

Verrotti

D'Egidio

Agostinelli

. Antiepileptic drug withdrawal in childhood epilepsy: what are the risk factors associated with seizure relapse? Eur J Paediatr Neurol. 2012;16(6):599–604.